Overview

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Mirati Therapeutics Inc.

Collaborator:

Bristol-Myers Squibb

Treatments:

Docetaxel
Nivolumab